Group 1 - The core point of the article is that Huaren Pharmaceutical has received approval from the National Medical Products Administration for its product "Nafamostat Mesilate Injection" [1] - Huaren Pharmaceutical's revenue composition for the first half of 2025 shows that the pharmaceutical industry accounts for 95.79% and the pharmaceutical commerce accounts for 4.21% [1] - As of the report date, Huaren Pharmaceutical has a market capitalization of 4 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated 80 billion USD in overseas licensing this year [1] - It highlights a conversation with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine while the primary market faces fundraising challenges [1]